Belgium’s food safety agency AFSCA-FAVV has ordered Ferrero to suspend production at its plant in Arlon, Belgium due to a link that has been confirmed between more than a hundred cases of salmonella and Kinder chocolate production.
According to AFSCA-FAVV, the decision to temporarily close the plant was taken after finding the information from Ferrero to be incomplete.
Ferrero, the Italian chocolate giant, canceled a number of its Kinder products last week owing to salmonella concerns.
The tainted chocolate was made at Ferrero's Arlon plant, where salmonella was discovered in a filter in December.
According to the Food Standards Agency in the United Kingdom, at least 63 instances of salmonella have been connected to Kinder products, with the majority of the cases occurring in children under the age of five.
Other countries affected by recalls included the US and several European states.
Ferrero acknowledged internal inefficiencies that caused delays in retrieving and sharing information promptly.
Ferrero revealed that the plant would only reopen once certified by the authorities.


Bank of America's $72.5M Epstein Settlement: What You Need to Know
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar
U.S. Jobs Market Eyes March Recovery Amid Inflation Pressures
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production
Iran Allows Oil Tankers Through Strait of Hormuz Amid U.S. Negotiations
U.S. Praises Kurdistan's Role in Oil Markets Amid Iran War Fallout
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 



